Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2014 AGM of Orion Corporation
ORION CORPORATIONÂ Â Â Â STOCK EXCHANGE RELEASE 30 JANUARY 2014 at 11.40 a.m.
Recommendation by the Nomination Committee concerning Board of Directors to be
elected by the 2014 AGM of Orion Corporation
The Nomination Committee of Orion Corporation has given on 30 January 2014 its
recommendation to the Board of Directors of the company for the proposal to the
Annual General Meeting of 2014 concerning the composition of the Board of
Directors to be elected. The Committee recommends that the following proposal be
presented to the AGM of 2014:
The number of Board members would be seven.
The present Board members, Sirpa Jalkanen, Eero Karvonen, Timo Maasilta, Hannu
SyrjÃ¤nen, Heikki Westerlund and Jukka YlppÃ¶ would be re-elected and Mikael
Silvennoinen, M. Sc. (Economics) would be elected as a new member for the next
term of office.
Hannu SyrjÃ¤nen would be re-elected as Chairman.
Mikael Silvennoinen, M. Sc. (Economics), born 1956, is the executive chairman of
Â IMS Talent Oy. Silvennoinen has over 20 years experience of management
positions in Pohjola Bank Plc, lastly (1997-2013) as the President and CEO and
Chairman of the Executive Committee of the bank. Previously he has worked in
various treasury positions in WÃ¤rtsilÃ¤ Corporation, lastly as a Group treasurer.
Silvennoinen is the Chairman of the Board of IMS Talent Oy and a board member in
Konecranes Plc Â and The Finnish Foundation for Share Promotion (Suomen
PÃ¶rssisÃ¤Ã¤tiÃ¶). His earlier positions of trust include among others position of
Chairman of Â the Board of Directors in Pohjola Insurance Ltd, Pohjola Asset
Management Ltd and Helsinki OP Retail Bank Plc as well as board memberships in
Pohjola Group Oyj Â and Unico Banking Group.
The Nomination Committee also announces as its recommendation that the following
remunerations be paid to the Board of Directors:
As an annual fee, the Chairman would receive EUR 76,000, the Vice Chairman would
receive EUR 51,000 and the other members would receive EUR 38,000 each. As a fee
for each meeting attended, the Chairman would receive EUR 1,200, the Vice
Chairman would receive EUR 900 and the other members would receive EUR 600 each.
The travel expenses of the Board members would be paid in accordance with
previously adopted practice. The aforementioned fees would also be paid to the
Chairmen and to the members of the committees established by the Board, for each
committee meeting attended.
Of the annual fee, 60% would be paid in cash and 40% in Orion Corporation B-
shares, which would be acquired to the members during 31 March-4 April 2014 from
the stock exchange in amounts corresponding to EUR 30,400 for the Chairman, EUR
20,400 for the Vice Chairman and EUR 15,200 for each of the other members. The
part of the annual fee that is to be paid in cash corresponds to the approximate
sum necessary for the payment of the income taxes on the fees and would be paid
no later than 30 April 2014. The annual fees shall encompass the full term of
office of the Board of Directors.
The Nomination Committee has not given its recommendation for the remunerations
to the Board of Directors, but the matter will be proposed by a shareholder at
The Nomination Committee has consisted of the following members: Matti Kavetvuo,
Chairman, Kari Jussi Aho, Timo Ritakallio, Seppo Salonen, Hannu SyrjÃ¤nen and
Timo Lappalainen Â Â Olli Huotari
President and CEO SVP, Corporate Functions
Hannu SyrjÃ¤nen, Chairman of the Board of Directors of Orion Corporation
phone +358Â 400Â 454 885
A photograph of Mikael Silvennoinen is downloadable from:
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and EasyhalerÂ® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via GlobeNewswire